Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1098

Prevention of Surgical Adhesions Using Tyrosine Kinase Inhibitors

Inventors: Mark Puder, Arin Greene

Invention Types: Therapeutics

Research Areas: Internal Medicine, Surgery/Wound Healing

Keywords: Method of Use, Surgery

For More Information Contact:  Khunkhun, Rajinder

 

Invention Description:

Surgeons at Boston Children's Hospital have uncovered a therapeutic technology that minimizes or prevents adhesions, the joining of two normally separate surfaces due to trauma or inflammation, following a surgical procedure. Administration of inhibitors of tyrosine kinase inhibitors such as Sunitinib with surgery in mice and rabbits was observed to inhibit post surgical adhesion formation.

||The present invention also may have tremendous impact on preventing, treating, or minimizing keloid or hypertrophic scars, implant contractures, or scarring after skin incisions.

||Adhesions formed following surgery frequently cause postoperative pain, blockage of intestines, and infertility. Adhesions are the major cause of intestinal obstruction and it is estimated that following an intra-abdominal procedure, adhesions occur in 50 to 80 percent of patients. Intestinal obstruction caused by adhesions leads to prolonged hospital stays, additional abdominal surgery, and even death. Adhesion formation is responsible for up to 30% of infertility cases. The financial burden due to complications of surgical adhesions is $1 billion and account for 846,000 inpatient days annually in the U.S. Adhesion formation is also problematic in extra-abdominal surgeries, such as in the hand, where impediment of movement is frequently troublesome to the patient. The prevention of adhesions would profoundly decrease morbidity, infertility, and reduce health care costs across a broad range of medical disciplines.

Applications:

General Surgery|Abdominal Surgery|Wound Healing

Competitive Advantages:

There are currently no therapeutics available to prevent surgical adhesions. The current standard of care is additional surgery. A small molecule inhibitor for use in this application represents a high margin, large market opportunity, and has the potential to be rapidly adopted as the standard of care.

Business Opportunity:

Exclusive License

Key Publications: Inhibition of intra-abdominal adhesion formation with the angiogenesis inhibitor sunitinib.

||Kim S, Lee S, Greene AK, Arsenault DA, Le H, Meisel J, Novak K, Flynn E, Heymach JV, Puder M.

||J Surg Res. 2008 Sep;149(1):115-9. Epub 2007 Nov 21.

Related Publications: Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib.
|Greene AK, Alwayn IP, Nose V, Flynn E, Sampson D, Zurakowski D, Folkman J, Puder M.|Ann Surg. 2005 Jul;242(1):140-6.

IPStatus: Pat. Pend.